Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson’s disease (PD) depending on the form
Background: Neurotrophic factors (NF) are polypeptide compounds that are synthesized by neurons and glial cells and are involved in regulating the growth process.
Method: A total of 88 patients were screened to assess the role and importance of glial neurotrophic factor in the early detection of Parkinson’s disease. 78 patients with PC disease and 10 patients who did not have PC disease in the control group. Of the patients examined in the main group, 39 (50%) were men and 39 (50%) were women. Accordingly, the control group consisted of 5 men (50%) men and 5 women (50%). The average age of male patients with PC was 18-70 years, with an average age of 52.6 ± 11.1 years, and the average age of women was 32-68 years, with an average age of 59.7 ± 10.9 years. The duration of the disease was 4.1 ± 5.6 years in men and 6.32 ± 5.8 years in women. GDNF levels were determined by enzyme immunoassay.
Results: The results of measurements were obtained that in the blood serum of patients of the main group, the amount of glial neurotic inflammation was 34.655±7.5 pg/ml, in the control group 73.558±8.2 pg/ml, (p<0.05). In the next phase of the study, we found it necessary to perform a comparative analysis of serum GDNF in patients with various clinical forms of PC. The results show that the amount of GDNF in the akinetic rigid form is 35.5 ± 4.8 pg / ml, in the vibratory form of the disease – 31.5 ± 5.7 pg / ml, and in the vibratory form of the disease – 30.21 ± 4.8 pg / ml. , in the mixed form of the disease was 28.2 ± 4.8 pg / ml, while in the early stages of the disease in 25 patients this figure was 38.2 ± 6.7 pg / ml.
Conclusion: A decrease of glial neurotrophic factor in the early stages of the disease indicates the onset of degeneration of dopaminergic neurons. Begins to decrease along the series of akinetic-rigid, tremor and mixed forms.
To cite this abstract in AMA style:B. Muminov, R. Matmurodov, E. Abduqodirov. Changes in the level of glial neurotrophic factor in Parkinson’s disease depending on the form [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/changes-in-the-level-of-glial-neurotrophic-factor-in-parkinsons-disease-depending-on-the-form/. Accessed September 27, 2023.
« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/changes-in-the-level-of-glial-neurotrophic-factor-in-parkinsons-disease-depending-on-the-form/